Additionally, an expert physician panel in Europe reached consensus and published a new recommended fibroid treatment algorithm with transcervical radiofrequency ablation (Sonata) at the forefront Redwood City, CA, June 1, 2021 – Gynesonics®, a women’s healthcare company focused on the development
Gynesonics Announces Publication of SAGE Global Registry Preliminary Results: Real-World Usage Corroborates the Safety and Applicability of Sonata Transcervical Fibroid Ablation
The initial results of the first 160 treated women in the Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry (SAGE) show the broad applicability of Transcervical Fibroid Ablation performed by the Sonata System to a wide range of fibroid types and sizes while maintaining an
Gynesonics Announces Publication of Clinical Study Analysis Demonstrating Effectiveness of the Sonata System in Treating Submucous and Large Symptomatic Uterine Fibroids
The analysis shows that fibroids, which are often treated by hysteroscopic resection or morcellation, can be effectively treated with the Sonata® System, the only incision-free, transcervical procedure that can treat most submucous, intramural, subserous, transmural and large fibroids REDWOOD CITY,
Gynesonics Appoints Susan Stimson To Its Board of Directors
Executive with Extensive Commercialization Experience to Provide Key Insights on Global Launch Strategies Redwood City, CA, March 18, 2021– Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that
Gynesonics Announces Positive Payer Coverage Issued by Health Care Service Corporation (HCSC) for the Sonata Treatment
HCSC is the largest customer-owned health insurer in the United States, operating Blue Cross and Blue Shield® Plans in Illinois, Montana, New Mexico, Oklahoma, and Texas Redwood City, CA, March 15, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive
Gynesonics Announces Centers for Medicare and Medicaid Services Final Rule Approves Ambulatory Surgery Centers as a Site of Service for Transcervical Uterine Fibroid Ablation with Device Intensive Designation
2021 Ruling Also Increases Hospital Outpatient Payment for the Associated Ambulatory Payment Classification That Covers the Sonata Treatment Redwood City, CA, March 9, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine
Gynesonics Announces that Detroit Medical Center Huron Valley-Sinai Hospital has Introduced Sonata, a New Innovative, Incision-Free Treatment for Symptomatic Uterine Fibroids
Detroit Medical Center’s Danny Benjamin, M.D., FACOG, Chief of Obstetrics and Gynecology at DMC Huron Valley-Sinai Hospital, is the first to provide the uterus-preserving, outpatient treatment option to women in Michigan Redwood City, CA, January 21, 2021 – Gynesonics®, a women’s healthcare
Sonata, a New Innovative, Incision-Free Treatment for Symptomatic Uterine Fibroids, has been Introduced in the MedStar Health System
MedStar Health is the first health system to provide Sonata, an incision-free, uterus-preserving, outpatient treatment option for women in the Maryland and Washington D.C. area Redwood City, CA - December 21, 2020 - Gynesonics®, a women’s healthcare company focused on the development of minimally
